Respiratory Syncytial Virus – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of respiratory syncytial virus (RSV) infection comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report both the incidence and prevalence of RSV infection for each country as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s RSV forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, together with the launch of the RSV vaccine affect the epidemiology of RSV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following RSV subpopulations:
- Live births by gestational age status.
- Pediatric inpatients by risk group status.
- Pediatric outpatients by risk group status.
- Inpatients aged 0-4 years.
- Outpatients aged 0-4 years.
- Singleton pregnancy status.
Note: Coverage may vary by country.
Table of contents
- Respiratory Syncytial Virus - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Event Rate of Respiratory Syncytial Virus per 1,000 People of All Ages in 2021 and 2041
- Event Rate of Respiratory Syncytial Virus per 1,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in Events of Respiratory Syncytial Virus Over the Next 20 Years
- Relative Sizes of the Contributing Factors to the Trend in Events of Respiratory Syncytial Virus Over the Next 20 Years
- Analysis of the Events of Respiratory Syncytial Virus in 2021, by Age
- Analysis of the Events of Respiratory Syncytial Virus in 2021, by Age
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.